Products for Research Use Only

SAR407899

CAT: 0804-HY-15687A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15687A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SAR407899 is a selective, potent and ATP-competitive ROCK inhibitor, with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively. SAR407899 shows stable inhibition of migrasome formation.
CAS Number
923359-38-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
ROCK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/SAR407899.html
Purity
99.60
Solubility
DMSO : 6 mg/mL (warming)
Smiles
O=C(NC=C1)C(C1=C2)=CC=C2OC3CCNCC3
Molecular Formula
C14H16N2O2
Molecular Weight
244.29
Precautions
H302, H315, H319, H335
References & Citations
[1]L?hn M, et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension. 2009 Sep;54 (3) :676-83.|[2]Guagnini F, et al. Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. J Transl Med. 2012 Mar 23;10:59.|[3]Puzhong Lu, et al. Chemical screening identifies ROCK1 as a regulator of migrasome formation. Cell Discov. 2020 Aug 4;6 (1) :51.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
ROCK1; ROCK2
Citation 01
Adv Sci (Weinh) . 2025 May;12 (17) :e2409870.|JCI Insight. 2018 Jun 7;3 (11) . pii: 98921.|Science. 2017 Dec 1;358 (6367) :eaan4368.